Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Finerenone

FDA-approved product (tablet, oral), marketed as Kerendia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Finerenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aldosterone antagonists
FDA pharmacologic class
Nonsteroidal Mineralocorticoid-Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Finerenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Finerenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

    NCT05924620 · start 2023-06-21

    Registered record
    Registry ID
    NCT05924620
    Conditions
    Primary Aldosteronism
    Interventions
    finerenone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-06-21
    Completion
    2024-03-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Aldosteronism
    Interventionfinerenone
    PhasePhase 4
    Registry statusCompleted

  • An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

    NCT05703880 · start 2023-06-01

    Registered record
    Registry ID
    NCT05703880
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes Mellitus
    Interventions
    Finerenone (Kerendia, BAY948862)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-01
    Completion
    2024-10-01
    Enrolment
    15,948

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes Mellitus
    InterventionFinerenone (Kerendia, BAY948862)
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants

    NCT07116512 · start 2023-05-02

    Registered record
    Registry ID
    NCT07116512
    Conditions
    Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent; Healthy Volunteers
    Interventions
    Finerenone (BAY94-8862): intervention A; Finerenone (BAY94-8862): intervention B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-05-02
    Completion
    2023-07-28
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent; Healthy Volunteers
    InterventionFinerenone (BAY94-8862): intervention A; Finerenone (BAY94-8862): intervention B
    PhasePhase 1
    Registry statusCompleted

  • Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

    NCT05814770 · start 2023-05

    Registered record
    Registry ID
    NCT05814770
    Conditions
    Primary Aldosteronism; Hypertension
    Interventions
    Finerenone; Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-05
    Completion
    2026-03
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Aldosteronism; Hypertension
    InterventionFinerenone; Spironolactone
    PhasePhase 4
    Registry statusUnknown

  • An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

    NCT05640180 · start 2022-11-23

    Registered record
    Registry ID
    NCT05640180
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes
    Interventions
    Finerenone (Kerendia, BAY94-8862); Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-11-23
    Completion
    2023-12-20
    Enrolment
    17,847

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes
    InterventionFinerenone (Kerendia, BAY94-8862); Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

    NCT05526157 · start 2022-10-01

    Registered record
    Registry ID
    NCT05526157
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes Mellitus
    Interventions
    Finerenone (Kerendia, BAY 948862); Sodium-glucose cotransporter 2 inhibitors (SGLT2i); Glucagon-like peptide-1 receptor agonists (GLP 1 RA); Steroidal mineral corticoid receptor antagonists (sMRA); Non-steroidal mineral corticoid receptor antagonists (nsMRA)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2024-09-05
    Enrolment
    50,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes Mellitus
    InterventionFinerenone (Kerendia, BAY 948862); Sodium-glucose cotransporter 2 inhibitors (SGLT2i); Glucagon-like peptide-1 receptor agonists (GLP 1 RA); Steroidal mineral corticoid receptor antagonists (sMRA) +1 more
    PhaseNot recorded
    Registry statusCompleted

  • A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

    NCT05348733 · start 2022-06-13

    Registered record
    Registry ID
    NCT05348733
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes Mellitus
    Interventions
    Kerendia (Finerenone, BAY94-8862)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-06-13
    Completion
    2026-12-22
    Enrolment
    4,613

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes Mellitus
    InterventionKerendia (Finerenone, BAY94-8862)
    PhaseNot recorded
    Registry statusActive not recruiting

  • An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

    NCT05013008 · start 2021-08-18

    Registered record
    Registry ID
    NCT05013008
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes Mellitus
    Interventions
    Finerenone (Kerendia, BAY94-8862); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-08-18
    Completion
    2021-12-31
    Enrolment
    951

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes Mellitus
    InterventionFinerenone (Kerendia, BAY94-8862); Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)

    NCT04795726 · start 2021-03-10

    Registered record
    Registry ID
    NCT04795726
    Conditions
    Diabetic Retinopathy
    Interventions
    Finerenone (BAY94-8862); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-03-10
    Completion
    2021-06-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Retinopathy
    InterventionFinerenone (BAY94-8862); Placebo
    PhaseNot applicable
    Registry statusCompleted

  • A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

    NCT04477707 · start 2020-07-23

    Registered record
    Registry ID
    NCT04477707
    Conditions
    Diabetic Retinopathy
    Interventions
    Finerenone (BAY94-8862)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-23
    Completion
    2021-06-25
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Retinopathy
    InterventionFinerenone (BAY94-8862)
    PhaseNot recorded
    Registry statusCompleted

  • Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

    NCT02957396 · start 2016-11-17

    Registered record
    Registry ID
    NCT02957396
    Conditions
    Pharmacokinetics
    Interventions
    Finerenone (BAY94-8862): 20 mg intact tablet; Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet; Finerenone (BAY94-8862): 20 mg suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-11-17
    Completion
    2017-03-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionFinerenone (BAY94-8862): 20 mg intact tablet; Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet; Finerenone (BAY94-8862): 20 mg suspension
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

    NCT02540993 · start 2015-09-17

    Registered record
    Registry ID
    NCT02540993
    Conditions
    Chronic Kidney Disease
    Interventions
    Finerenone (BAY94-8862); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09-17
    Completion
    2020-04-14
    Enrolment
    5,734

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionFinerenone (BAY94-8862); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

    NCT02545049 · start 2015-09-17

    Registered record
    Registry ID
    NCT02545049
    Conditions
    Diabetic Kidney Disease
    Interventions
    Finerenone (BAY94-8862); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-09-17
    Completion
    2021-02-02
    Enrolment
    7,352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease
    InterventionFinerenone (BAY94-8862); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone

    NCT01955694 · start 2013-11-11

    Registered record
    Registry ID
    NCT01955694
    Conditions
    Heart Failure
    Interventions
    BAY94-8862; Eplerenone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-11-11
    Completion
    2015-02-20
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionBAY94-8862; Eplerenone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

    NCT01968668 · start 2013-10-28

    Registered record
    Registry ID
    NCT01968668
    Conditions
    Diabetic Nephropathies
    Interventions
    BAY94-8862; BAY94-8862; BAY94-8862; BAY94-8862; BAY94-8862; Placebo; BAY 94-8862; BAY 94-8862
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10-28
    Completion
    2014-11-07
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathies
    InterventionBAY94-8862; BAY94-8862; BAY94-8862; BAY94-8862 +4 more
    PhasePhase 2
    Registry statusCompleted